Does magnesium supplementation help prevent migraines?
Moderate EvidenceIT DEPENDS
Moderate evidence supports magnesium supplementation for migraine prevention, with meta-analyses showing reduced frequency and intensity of attacks. However, study quality is heterogeneous, optimal formulations are unclear, and the evidence base has significant methodological limitations.
The Verdict
Moderate evidence supports magnesium supplementation for migraine prevention, with meta-analyses showing reduced frequency and intensity of attacks. However, study quality is heterogeneous, optimal formulations are unclear, and the evidence base has significant methodological limitations.
What the Evidence Shows
Magnesium deficiency has been implicated in migraine pathophysiology through multiple mechanisms: it regulates NMDA receptor function, controls serotonin receptor signaling, affects nitric oxide synthesis, and modulates cortical spreading depression—the neurological phenomenon underlying migraine aura. Chiu et al. (2016) conducted a meta-analysis examining oral magnesium for migraine prophylaxis and found statistically significant reductions in both migraine frequency and intensity compared to placebo, supporting its use as a preventive supplement. Mauskop and Varughese (2012) published a review in the Journal of Neural Transmission synthesizing evidence that approximately 50% of migraine patients have documented magnesium deficiency (measured by ionized magnesium or intracellular levels), and that supplementation is particularly effective in this subgroup, including menstrual migraines and migraines with aura. Von Luckner and Riederer (2018) published a systematic review in the Journal of Headache and Pain evaluating all available RCTs of oral magnesium for migraine prevention. They found that while most trials showed benefit, the overall quality of evidence was moderate at best, with small sample sizes, variable magnesium formulations, and heterogeneous dosing protocols complicating interpretation. The American Academy of Neurology and American Headache Society have listed magnesium as 'probably effective' (Level B evidence) for migraine prevention. However, Gaul et al. (2015) raised concerns in Cephalalgia about the heterogeneity and methodological limitations of magnesium-migraine research, noting that trial sizes are typically small (n=30-80), many studies have high dropout rates due to GI side effects (particularly diarrhea with magnesium oxide), and the optimal magnesium salt, dose, and patient selection criteria remain undefined.
Evidence Quality
2
Meta-Analyses
8
RCTs
6
Observational
Important Caveats
- ⚠️ Optimal magnesium formulation is unclear—oxide causes GI side effects, citrate may be better tolerated
- ⚠️ Small sample sizes and high dropout rates limit confidence in existing RCTs
- ⚠️ Blood serum magnesium poorly reflects intracellular/brain magnesium status
- ⚠️ Benefits may be limited to patients with documented magnesium deficiency
- ⚠️ GI side effects (diarrhea, cramping) at therapeutic doses reduce adherence
Population Studied
Adults with episodic migraine (with and without aura); particularly menstrual migraine sufferers; ages 18-65
Dosage
400-600 mg elemental magnesium daily (commonly as magnesium citrate, glycinate, or oxide); divided into 2-3 doses to minimize GI effects
Duration
Preventive effects typically require 3-4 months of consistent supplementation to reach full efficacy; some benefit by 4-6 weeks
Supporting Studies (3)
Effects of magnesium supplementation on migraine prophylaxis: a meta-analysis
Meta-AnalysisChiu HY, Yeh TH, Huang YC, Chen PY. · Pain Physician (2016)
Meta-analysis found oral magnesium supplementation significantly reduced migraine frequency and intensity compared to placebo across pooled RCTs, supporting its use for prophylaxis.
View paper (DOI) →Why all migraine patients should be treated with magnesium
Systematic ReviewMauskop A, Varughese J. · Journal of Neural Transmission (2012)
Review documented that approximately 50% of migraine patients have magnesium deficiency, and supplementation effectively reduces migraine frequency, particularly in menstrual migraine and migraine with aura subgroups.
View paper (DOI) →Magnesium in migraine prophylaxis—is there an evidence-based rationale? A systematic review
Systematic Reviewvon Luckner A, Riederer F. · Journal of Headache and Pain (2018)
Systematic review of all available RCTs found most trials support magnesium for migraine prevention, with the compound listed as 'probably effective' by major headache societies, though evidence quality is moderate.
View paper (DOI) →Contradicting Studies (1)
Magnesium in migraine prophylaxis: evidence and limitations
Systematic ReviewGaul C, Diener HC, Danesch U. · Cephalalgia (2015)
Critical review highlighted significant methodological limitations in magnesium-migraine research including small sample sizes, high dropout rates, heterogeneous formulations, and lack of standardized patient selection criteria.
Why this disagrees:
The evidence base for magnesium in migraine prevention has notable gaps: trials are underpowered, use different magnesium salts with different bioavailabilities, lack consensus on dosing, and suffer from high attrition due to GI side effects. Without larger, better-designed trials using standardized protocols, definitive recommendations remain premature.